Switzerland-based Roche has entered into a partnership with Alnylam Pharmaceuticals Inc to co-develop and commercialise an experimental RNA interference (RNAi) therapeutic that has shown promise as a treatment for hypertension in patients at a high risk of cardiovascular disease. Announced on 24 July, the deal involves zilebesiran, a drug currently in Phase 2 which targets angiotensinogen, a protein implicated in the renin-angiotensin-aldosterone system which causes high blood pressure.
